Drugs / EDI200
EDI200
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01564225 | May 2012 → Apr 2013 | X-linked hypohidrotic ectodermal dysplasia | Edimer Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04980638 | Apr 2022 → Feb 2027 expected | X-linked hypohidrotic ectodermal dysplasia | EspeRare Foundation | Recruiting | No outcome recorded |
| Phase 2 | NCT01775462 | Apr 2013 → Dec 2015 | X-linked hypohidrotic ectodermal dysplasia | Edimer Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDI200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01775462 ↗ |
| Known as | APO200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297944 ↗ |
| Known as | ER004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04980638 ↗ |
| Known as | Fc:eda-a1 fusion protein | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297944 ↗ |
| Action | Restore | “The proposed mechanism of action of ER004 is the replacement of the missing EDA1 protein in patients with XLHED.” NCT04980638 ↗ |
| Modality | Protein / enzyme biologic | “EDI200, an EDA-A1 Replacement Protein” NCT01775462 ↗ |
| Route | Other | “Intra-amniotic route” NCT04980638 ↗ |